Please login first

Webinar on Clinical Medicine | Updates on Leukemia in Children, Myelodysplastic Syndromes and Red Blood Cell Diseases

4 May 2022, 09:00 (CEST)

Acute Leukemia, Children, Immunotherapy, Myelodysplastic Syndrome, Targeted Therapy, Erythropoiesis, Infection, Malaria, Thalassemia
Bookmark event Remove event from bookmarks
Add this event to bookmarks
Event Registration Contact Us

Welcome from the Chair

7th Webinar on Clinical Medicine

Updates on Leukemia in Children, Myelodysplastic Syndromes and Red Blood Cell Diseases

The webinar will discuss the advances which have been made over the years in the characterization and treatment of children leukemia. The detailed analysis of genetic alterations has identified subgroups of patients who will profit from adapted therapies including newer immunotherapeutic strategies using monoclonal antibodies, bispecific antibodies, immunotoxins, chimeric antigen receptor (CAR) T cells and allogeneic stem cell transplantation for front-line treatment and for relapses. Guidance will be given for the treatment of children with chronic myeloid leukemia (CML) and successful treatment strategies will be discussed for patients who live in countries with less resources and less access to all new therapeutic approaches. New developments will be discussed in the treatment of mainly elderly patients with myelodysplastic syndrome (MDS) based on the availability of next-generation sequencing (NGS). Patients’ with MDS and their unmet needs are reviewed, and a broader understanding of novel biological findings should lead to improve the health-related quality of life of these mainly elderly patients. Finally, hereditary diseases of red blood cells and especially the pathophysiology of erythropoiesis-related infectious diseases will be discussed, and a comprehensive review of diagnosis and therapy will be provided.

Date: 4 May 2022

Time: 9:00 am CEST | 3:00 am EDT | 3:00 pm CST Asia | 4:00 pm JST

Webinar ID: 837 8883 5086

Webinar Secretariat:


Department of General Pediatrics, Hematology and Oncology, Children's University Hospital Tübingen, Tübingen, Germany

Dr. Handgretinger is Professor emeritus of Pediatrics. He reveiced his medical training at the Children’s University Hospital Tuebingen, Germany. From 2000-2005, he was the director of the division of stem cell transplantation at St.Jude Children’s Research Hospital in Memphis, USA. From 2006-2021 he was the Chairman of the Department of General Pediatrics and Hematology/Oncology at Children’s University Hospital, Tübingen, Germany. He is currently a consultant at the Abu Dhabi Stem Cell Center and Yas clinic Khalifa City. Dr. Handgretinger’s main research interests have been cellular immunotherapeutic approaches to the treatment of children with various forms of cancer. He was one of the first to introduce immunotherapy with bispecific antibodies in children with relapsed/refractory acute lymphoblastic leukemia and is also involved in clinical trials using anti-CD19 and anti-CD19/22 CAR’s in pediatric R/R ALL. He pioneered the T-cell receptor alpha/beta depletion technology in allogeneic transplantation. He received various prices and is a member of the german national academy of science Leopoldina. In 2021, he received the Lifetime Achievement Award from the american Pediatric Transplantation and Cellular Therapy Consortium (PTCTC).

Invited Speakers

Grande Ospedale Metropolitano, Reggio Calabria, Italy

Esther Natalie Oliva earned degrees in Medicine and Surgery from the University of Messina, Italy, in 1990. In 1994, she received a degree in General Haematology from the same university. From 1991 to 1997, she earned a Mario Negri Institute research grant to conduct research at the Nephrology Unit of the Azienda Ospedaliera “Bianchi-Melacrino-Morelli” in Reggio Calabria, Italy. Since 1998 she has been a practicing haematologist at the Haematology Unit of the same hospital in Reggio Calabria, in charge of the Myelodysplastic Syndromes, Aplastic Anemia and Anemia section. Since 2018 she has a national scientific qualification for Associate Professor of Blood Diseases, Oncology and Rheumatology. Dr Oliva has developed a unique instrument for the evaluation of quality of life in myelodysplastic syndromes (QOL-E) and a specific instrument for the measurement of patient-reported outcomes in patients with Haematological malignancies (HM-PRO). She has also developed and coordinated clinical trials in pharmacological research and in quality-of-life search. She is founder member since 2007 and since 2029 Vice President of Associazione QOL-ONE, a non-profit association for scientific research. She is the Co-Chair of the EHA Scientific Working Group Quality of Life and Symptoms and is an active member of the American Society of Hematology, the European Haematology Association, the International Society of Quality of Life and the Italian Society of Hematology.

Department of Medical Technology and Sciences, International University of Health and Welfare, Ohkawa, Fukuoka, Japan

Tsukuru Umemura is the professor of International University of Health and Welfare, Director of Clinical Laboratory, Kouhoukai Takagi Hosiptal. His major research interests are microRNA, extracellular vesicle (EV), Molecular mechanism of erythropoiesis, microRNAs in malaria and other infectious diseases.

Webinar Content

To view this content, you need to be registered and logged in to Sciforum platform.



Time in CEST

Time in JST

Prof. Dr. Rupert Handgretinger

Chair Introduction

9:00 - 9:10 am

4:00 - 4:10 pm

Prof. Dr. Rupert Handgretinger

Advances in the Classification and Therapy of Pediatric Acute Lymphoblastic Leukemia

9:10 - 9:40 am

4:10 - 4:40 pm

Dr. Esther Natalie Oliva

Patient-Reported Outcomes in Myelodysplastic Syndromes

9:40 - 10:10 am

4:40 - 5:10 pm

Prof. Dr. Tsukuru Umemura

The Signatures of Circulating Extracellular Vesicles in Hematological Diseases

10:10 - 10:40 am

5:10 - 5:40 pm

Q&A Session

10:40 - 10:55 am

5:40 - 5:55 pm

Closing of Webinar
Prof. Dr. Rupert Handgretinger

10:55 - 11:00 am

5:55 - 6:00 pm

Relevant SI

Advance in the Treatment of Pediatric Leukemia
Guest Editor: Prof. Dr. Rupert Handgretinger
Deadline for manuscript submissions: closed (30 June 2021)

Myelodysplastic Syndrome: Recent Advances and Future Directions
Guest Editor: Dr. Esther Natalie Oliva
Deadline for manuscript submissions: 20 July 2022

New Approaches to the Diagnosis and Management of Anemia and Malaria

Guest Editor: Prof. Dr. Tsukuru Umemura
Deadline for manuscript submissions: 25 July 2022

Sponsors and Partners